2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Excoriation Disorder: new trials by email Literature Review of Excoriation Disorder trials Research Report on Excoriation Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Guanfacine Extended Release, Placebo - Prader-Willi Syndrome, Aggression | Phase 4 | Completed | Maimonides Medical Center | 15 | 2020-12-17 | 2024-08-19 |
| Escitalopram for the Treatment of Self-Injurious Skin Picking Escitalopram - Impulse Control Disorders | Phase 4 | Completed | Massachusetts General Hospital | 30 | 2002-09-01 | 2008-05-20 |
Abnormalities, Multiple (1) · Aggression (1) · Behavioral Symptoms (1) · Chromosome Disorders (1) · Congenital Abnormalities (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Genetic Diseases, Inborn (1) · Intellectual Disability (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Nutrition Disorders (1) · Obesity (1) · Overnutrition (1)
Anxiety Disorders (2) · Behavior (2) · Mental Disorders (2) · Obsessive-Compulsive Disorder (2) · Aberrant Motor Behavior in Dementia (1) · Behavioral Symptoms (1) · Body Weight (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Imprinting Disorders (1) · Neurodevelopmental Disorders (1) · Nutritional and Metabolic Diseases (1) · Overweight (1) · Pathological Conditions, Signs and Symptoms (1) · Self-Injurious Behavior (1)
Escitalopram (1) · Guanfacine (1)
Maimonides Medical Center (1) · Massachusetts General Hospital (1)
United States (2)
Deepan Singh, MD (1) · Nancy J Keuthen, Ph.D. (1)